Improvements in Productivity and Increased Participation in Daily Activities Over 52 Weeks of Certolizumab Pegol Treatment of Rheumatoid Arthritis: Results of a Belgian Observational Study

Acta Clinica Belgica - United Kingdom
doi 10.1080/17843286.2018.1509923
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

Informa UK Limited

Related search

Improvements in Productivity at Paid Work and Within the Household, and Increased Participation in Daily Activities After 24 Weeks of Certolizumab Pegol Treatment of Patients With Psoriatic Arthritis: Results of a Phase 3 Double-Blind Randomised Placebo-Controlled Study

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2014English

Cost-Effectiveness of Certolizumab Pegol in the Treatment of Active Rheumatoid Arthritis, Axial Spondyloarthritis, and Psoriatic Arthritis in Romania

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Sustained Improvements in Workplace and Household Productivity and Social Participation With Certolizumab Pegol Over 96 Weeks in Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Predictors of Sick Leave and Improved Worker Productivity After 52 Weeks of Intensive Treatment in Patients With Early Rheumatoid Arthritis

Scandinavian Journal of Rheumatology
MedicineRheumatologyAllergyImmunology
2019English

Certolizumab Pegol in the Treatment of Axial Spondyloarthritis

Nauchno-Prakticheskaya Revmatologiya
RheumatologyAllergyImmunology
2015English

Efficacy and Safety of Bimekizumab as Add-On Therapy for Rheumatoid Arthritis in Patients With Inadequate Response to Certolizumab Pegol: A Proof-Of-Concept Study

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2019English

Pms77 - Decline in Healthcare Resource Consumption for Patients With Rheumatoid Arthritis Starting Certolizumab Pegol Therapy in France (The Eclair Study)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Certolizumab Pegol for the Treatment of Crohn’s Disease

Therapeutic Advances in Gastroenterology
Gastroenterology
2011English

Certolizumab Pegol Is Associated With Long-Term Improvements in Patient-Reported Outcomes in Psoriatic Arthritis: 4-Year Outcomes From the Rapid-Psa Study

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy